1260757-70-7Relevant articles and documents
HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS
-
Page/Page column 102-103, (2021/02/19)
The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.
DISUBSTITUTED PYRAZOLE COMPOUNDS
-
Paragraph 0101; 0105, (2020/12/25)
The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and no
NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
-
Page/Page column 116-117, (2020/01/08)
The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
